PharmaVentures, the company behind the PharmaDeals(R) range of business information, announced today the expansion of its PharmaDeals Agreements coverage that includes exclusive interviews with deal makers around the world. The announcement follows major enhancement of its dedicated, market leading platform delivering deal data and information to the pharmaceutical and biotechnology sector.
The scope of PharmaDeals Agreements database has been expanded to include categories of deals that have medical and therapeutic applications in cosmetics, internet and e-commerce, nutritional supplements, packaging, wound care, bioterrorism, as well as deeper classifications within drug delivery technologies.
Fintan Walton, PhD, Chief Executive of PharmaVentures, says, "We are very excited about our latest version of PharmaDeals. One of the big issues that face those in researching and analysing deals is the lack of scope within databases they use which is a result of the huge changes taking place in the world of deal making. More companies are doing specialist deals, for example, with orphan drugs, and the world is changing as new technologies, mechanisms of action and even new therapy areas emerge. Frankly no one else has tried to come up with solutions to these changes."
New content is also being sourced related to deal making by Clinical Research and Contract Manufacturing Organizations. The development to the database augments recent improvements to the classifications and user interface.
As deal making is a people business subscribers can for the first time access exclusive television interviews with the key deal makers in the major pharmaceutical companies as well as key influencers at the corporate level such as CEOs and Board Members of corporations.
Dr Walton continues, "A key priority for us is to better serve our customers with information about deals from rapidly developing markets, and we have done this by considerably increasing our sources, especially in India, China, and generally within South Asia and South America. These developments to our content are additional key milestones for us, and, in the very near future, we shall be bringing news of further offerings to help our clients' ability to win the best deals for them."
UNIGE's synthetic anticoagulant provides reliable alternative to heparin